Key Highlights

  • Haleon (LSE:HLN) reported organic Revenue growth of 2.6% for H1 2026, accelerating to 3.1% in Q2
  • Oral health grew 7.3% in the half, led by Sensodyne and Parodontax
  • Adjusted operating profit rose 8.2% at constant currency, with Margin up 120 basis points
  • Adjusted Diluted Earnings per Share grew 12.0%
  • Generated about £0.8bn of free Cash Flow and returned £0.4bn in dividends plus £0.5bn in buybacks

Haleon delivered a stronger second quarter in the first half of 2026, with growth accelerating as its oral-health powerhouses Sensodyne and Parodontax led the charge. The consumer-health group — spun out of GSK in 2022 and home to brands including Panadol, Centrum, Voltaren and Advil — reported organic revenue growth of 2.6% for the six months to 30 June, but the more important number for investors was the sequential pick-up: organic growth quickened to 3.1% in the second quarter from 2.2% in the first. Reported revenue came in at around £5.6bn. Management framed the half as evidence that its "power brands" and innovation pipeline are regaining momentum after a patchier spell, and it reaffirmed full-year guidance.

Margins and cash do the heavy lifting

The profit story was arguably better than the top line. Adjusted operating profit rose 8.2% at constant currency, with the adjusted Operating Margin expanding 120 basis points at constant currency and gross margin up 140 basis points, reflecting productivity savings, premiumisation and easing input-cost pressures. Adjusted diluted earnings per share grew 12.0%, a reminder of how Buybacks and margin gains can amplify modest revenue growth into double-digit EPS progress. Haleon (LSE:HLN) generated roughly £0.8bn of free cash flow, returned about £0.4bn in dividends and repurchased around £0.5bn of shares, while net Debt stood at about 2.5 times adjusted EBITDA.

Oral health was the standout category, growing 7.3% over the half and 6.2% in the second quarter, driven by Sensodyne and Parodontax as sensitivity and gum-health ranges resonated across developed and emerging markets alike. Pain relief grew 2.1% in the half but accelerated sharply to 4.6% in the second quarter, while respiratory health declined 4.7%, a category that continues to lap unusually strong cold-and-flu seasons and remains volatile. The geographic mix leaned on the United States and emerging markets, which helped offset softer patches elsewhere.

For the full year, Haleon maintained its guidance of 3–5% organic revenue growth and high-single-digit growth in adjusted operating profit at constant currency. That implies further acceleration in the second half, a bar the market will judge against the pricing-led nature of the first-half performance: of the 2.6% organic growth, roughly 2.1 percentage points came from price and only about 0.5 from Volume and mix. Sustaining growth as pricing normalises will require volumes to do more of the work — a key watch-point for investors wary of relying on price increases indefinitely.

The strategic case for Haleon rests on the defensive, cash-generative qualities of everyday health brands with pricing power, strong shelf positions and long innovation runways. The company has continued to sharpen its portfolio, prioritising higher-growth categories and paying down the debt inherited at demerger. A cleaner Balance Sheet increasingly frees management to return more cash, and the combination of a progressive Dividend and ongoing buybacks is central to the Equity story.

Risks remain. Private-label competition is intensifying in some categories as squeezed consumers trade down, currency swings can flatter or dent reported numbers, and any renewed spike in input or freight costs would test the margin trajectory. Litigation and regulatory scrutiny — familiar features of the consumer-health sector — also linger in the background, as does the perennial question of whether a portfolio of mature brands can consistently outgrow its end markets.

Investors will focus on whether volume growth broadens, whether the second-half acceleration implied by guidance materialises, and on the pace of deleveraging and Capital returns. Haleon is not a high-growth story, but a strengthening second quarter, expanding margins and double-digit EPS growth make a reasonable case that its defensive model is delivering. The valuation, as ever, will hinge on how durable that momentum proves.